Suchergebnisse - "Pyridines therapeutic use"

Cyclin-dependent kinase 4 drives cystic kidney disease in the absence of mTORC1 signaling activity

Autoren: Florian Grahammer Bernhard Dumoulin Ramila E. Gulieva et al.

Quelle: Kidney international, vol. 106, no. 5, pp. 856-869
Kidney international 106(5), 856-869 (2024). doi:10.1016/j.kint.2024.08.021
Grahammer, F, Dumoulin, B, Gulieva, R E, Wu, H, Xu, Y, Sulaimanov, N, Arnold, F, Sandner, L, Cordts, T, Todkar, A, Moulin, P, Reichardt, W, Puelles, V G, Kramann, R, Freedman, B S, Busch, H, Boerries, M, Walz, G & Huber, T B 2024, 'Cyclin-dependent kinase 4 drives cystic kidney disease in the absence of mTORC1 signaling activity', Kidney International, vol. 106, no. 5, pp. 856-869. https://doi.org/10.1016/j.kint.2024.08.021

Schlagwörter: Mice, Knockout, Polycystic Kidney Diseases, CDK4, Pyridines, bypass mechanism, Cyclin-Dependent Kinase 4, Kinesins, Kidney Diseases, Cystic, Mechanistic Target of Rapamycin Complex 1, Piperazines, Mice, Disease Models, Animal, mTOR pathway, SDG 3 - Good Health and Well-being, Disease Progression, Animals, Humans, Cilia, cystic kidney disease, Protein Kinase Inhibitors, Cilia/pathology, Cilia/metabolism, Cyclin-Dependent Kinase 4/antagonists & inhibitors, Cyclin-Dependent Kinase 4/metabolism, Cyclin-Dependent Kinase 4/genetics, Kidney Diseases, Cystic/genetics, Kidney Diseases, Cystic/metabolism, Kidney Diseases, Cystic/pathology, Kidney Diseases, Cystic/drug therapy, Kinesins/genetics, Kinesins/metabolism, Kinesins/antagonists & inhibitors, Mechanistic Target of Rapamycin Complex 1/metabolism, Mechanistic Target of Rapamycin Complex 1/antagonists & inhibitors, Mechanistic Target of Rapamycin Complex 1/genetics, Piperazines/pharmacology, Piperazines/therapeutic use, Polycystic Kidney Diseases/genetics, Polycystic Kidney Diseases/metabolism, Polycystic Kidney Diseases/pathology, Polycystic Kidney Diseases/drug therapy, Protein Kinase Inhibitors/pharmacology, Protein Kinase Inhibitors/therapeutic use, Pyridines/pharmacology, Pyridines/therapeutic use, Signal Transduction

Dateibeschreibung: application/pdf; pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39218392
https://pure.eur.nl/en/publications/4e650091-2701-4069-b10a-dd417ac6599b
https://doi.org/10.1016/j.kint.2024.08.021
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_30EFFC9D3A8A1
https://serval.unil.ch/notice/serval:BIB_30EFFC9D3A8A
https://serval.unil.ch/resource/serval:BIB_30EFFC9D3A8A.P001/REF.pdf
https://publications.rwth-aachen.de/record/1007463

EFFECT of daily antiseptic bathing with octenidine on ICU-acquired bacteremia and ICU-acquired multidrug-resistant organisms: a multicenter, cluster-randomized, double-blind, placebo-controlled, cross-over study

Autoren: Tiffany Schaumburg Norbert Köhler Yasmine Breitenstein et al.

Quelle: Intensive Care Med

Schlagwörter: Male, Cross Infection, Cross-Over Studies, Original, Pyridines, Bacteremia, Baths, Middle Aged, Intensive Care Units/statistics, Double-Blind Method [MeSH], Cross Infection/prevention, Aged [MeSH], Octenidine, Intensive care unit, Male [MeSH], Bacteremia/prevention, Anti-Infective Agents, Local/pharmacology [MeSH], Imines [MeSH], Baths/methods [MeSH], Female [MeSH], Pyridines/pharmacology [MeSH], Drug Resistance, Multiple, Bacterial/drug effects [MeSH], Pyridines/therapeutic use [MeSH], Antiseptic bathing, Humans [MeSH], Pyridines/administration, Middle Aged [MeSH], Anti-Infective Agents, Local/therapeutic use [MeSH], Cross-Over Studies [MeSH], Anti-Infective Agents, Local/administration, Germany [MeSH], Multidrug-resistant organisms, Intensive Care Units, Double-Blind Method, Drug Resistance, Multiple, Bacterial, Germany, Anti-Infective Agents, Local, Humans, Female, Imines, Aged

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39417875
https://repository.publisso.de/resource/frl:6507122

Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine: novel drugs providing innovative opportunities in the management of migraine

Autoren: William David Wells-Gatnik Lanfranco Pellesi Paolo Martelletti

Quelle: Expert Review of Neurotherapeutics. 24:1107-1117

Schlagwörter: rimegepant, Piperidines/therapeutic use, Piperidines, Pyridines, Migraine Disorders, Migraine Disorders/drug therapy, Humans, CGRP, atogepant, Migraine, Pyridines/therapeutic use

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39264231

A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI)

Autoren: Alexander Yule Christabella Ng Arantxa Recto et al.

Quelle: Journal of cystic fibrosis, vol. 23, no. 5, pp. 984-990
Yule, A, Ng, C, Recto, A, Lockwood, F, Dellschaft, N S, Hoad, C L, Zagoya, C, Mainz, J G, Major, G, Barr, H L, Gowland, P A, Stewart, I, Marciani, L, Spiller, R C & Smyth, A R 2024, 'A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI)', Journal of Cystic Fibrosis, vol. 23, no. 5, pp. 984-990. https://doi.org/10.1016/j.jcf.2024.08.001

Schlagwörter: Male, Adult, Indoles, Cystic Fibrosis, Adolescent, Pyridines, Humans, Cystic Fibrosis/drug therapy, Cystic Fibrosis/physiopathology, Female, Magnetic Resonance Imaging/methods, Benzodioxoles/therapeutic use, Gastrointestinal Transit/drug effects, Longitudinal Studies, Prospective Studies, Aminophenols/therapeutic use, Pyrazoles/therapeutic use, Pyrazoles/pharmacology, Indoles/therapeutic use, Drug Combinations, Chloride Channel Agonists/therapeutic use, Quinolones/therapeutic use, Pyridines/therapeutic use, Pyridines/pharmacology, Cystic Fibrosis Transmembrane Conductance Regulator, Child, Quinolines/therapeutic use, Quinolines/pharmacology, Young Adult, Pyrrolidines/therapeutic use, CF, CFTR modulator, Cystic fibrosis, ETI, GI, MRI, elexacaftor/tezacaftor/ivacaftor, gastrointestinal, gut, magnetic resonance imaging, name=Pediatrics, Quinolones, Aminophenols, name=Pulmonary and Respiratory Medicine, Benzodioxoles, Gastrointestinal Transit, Chloride Channel Agonists, Perinatology, Magnetic Resonance Imaging, and Child Health, name=Pediatrics, Perinatology, and Child Health, Pyrazoles

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39242338
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_3D663DEB2F8C5
https://serval.unil.ch/notice/serval:BIB_3D663DEB2F8C
https://serval.unil.ch/resource/serval:BIB_3D663DEB2F8C.P001/REF.pdf
https://pure.qub.ac.uk/en/publications/07614c4d-4a86-4855-8799-bf0645425487

REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

Autoren: Stephan A. Mayer Nicolas Bruder Giuseppe Citerio et al.

Weitere Verfasser: Stephan A. Mayer Nicolas Bruder Giuseppe Citerio et al.

Quelle: Journal of Neurosurgery. :1-12

Schlagwörter: Male, Vasospasm, Intracranial/diagnostic imaging, Pyridines, Tetrazoles, cerebral ischemia, Brain Ischemia, Dioxanes, 0302 clinical medicine, Vasospasm, Intracranial, Pyridines/administration & dosage, Prospective Studies, Human health sciences, clazosentan, Vasospasm, Intracranial/prevention & control, Pyridines/therapeutic use, Sulfonamides, Subarachnoid Hemorrhage/diagnostic imaging, Anesthesia & intensive care, Middle Aged, Brain Ischemia/etiology, 3. Good health, Dioxanes/therapeutic use, Treatment Outcome, Neurology, Tetrazoles/therapeutic use, endothelin-1, Vasospasm, Intracranial/etiology, Dioxanes/adverse effects, Female, Tetrazoles/adverse effects, Adult, Anesthésie & soins intensifs, subarachnoid hemorrhage, vascular disorders, Sciences de la santé humaine, 03 medical and health sciences, Double-Blind Method, Neurologie, Humans, Pyrimidines/administration & dosage, Pyridines/adverse effects, aneurysm, cerebral vasospasm, Aged, Sulfonamides/administration & dosage, Pyrimidines/adverse effects, Pyrimidines/therapeutic use, Sulfonamides/adverse effects, Sulfonamides/therapeutic use, Subarachnoid Hemorrhage, Vasospasm, Intracranial/drug therapy, Pyrimidines, Subarachnoid Hemorrhage/complications, Surgery, Neurology (clinical), Brain Ischemia/prevention & control

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39126720

Regorafenib in patients with pretreated advanced melanoma: a single-center case series: a single-center case series

Autoren: Vander Mijnsbrugge, An-Sofie Cerckel, Justine Dirven, Iris et al.

Weitere Verfasser: Vander Mijnsbrugge, An-Sofie Cerckel, Justine Dirven, Iris et al.

Quelle: Melanoma Research. 34:366-375

Schlagwörter: Male, Adult, Aged, 80 and over, 0301 basic medicine, Skin Neoplasms, Pyridines, Phenylurea Compounds, Middle Aged, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Skin Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Humans, Melanoma/drug therapy, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, aged, 80 and over, Melanoma, Pyridines/therapeutic use, Phenylurea Compounds/therapeutic use, Aged, Retrospective Studies

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38801446
https://biblio.vub.ac.be/vubir/(4b97562c-35d2-4a10-82ea-02f89d33a032).html

Selective Internal Radiation Therapy Using Y-90 Resin Microspheres for Metastatic Colorectal Cancer: An Updated Systematic Review and Network Meta-Analysis

Autoren: André L. F. Azeredo-da-Silva Victor Hugo F. de Jesus Ion Agirrezabal et al.

Quelle: Adv Ther

Schlagwörter: Pyrrolidines, Pyridines, Phenylurea Compounds, Network Meta-Analysis, Brachytherapy, Microspheres, Trifluridine, Drug Combinations, Humans, SIRT, Phenylurea Compounds/therapeutic use [MeSH], Pyridines/therapeutic use [MeSH], Drug Combinations [MeSH], Humans [MeSH], Liver metastasis, Colorectal Neoplasms/drug therapy [MeSH], Regorafenib, Colorectal Neoplasms/radiotherapy [MeSH], Yttrium Radioisotopes/therapeutic use [MeSH], Thymine [MeSH], Brachytherapy/methods [MeSH], Phenylurea Compounds/adverse effects [MeSH], Microspheres [MeSH], Brachytherapy/adverse effects [MeSH], Trifluridine/therapeutic use [MeSH], Original Research, Best supportive, Pyrrolidines/therapeutic use [MeSH], Trifluridine–tipiracil, Yttrium Radioisotopes, Colorectal Neoplasms, Thymine

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38407790
https://repository.publisso.de/resource/frl:6502870

Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial

Autoren: Jain, R.K. Swami, U. Bilen, M.A. et al.

Schlagwörter: WCM Library Coordinated Deposit, Humans, Antibodies, Monoclonal, Humanized/therapeutic use/administration &, dosage/adverse effects/pharmacology, Male, Anilides/therapeutic use/administration & dosage/adverse effects/pharmacology, Female, Pyridines/therapeutic use/administration & dosage/adverse effects/pharmacology, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects, Middle Aged, Carcinoma, Transitional Cell/drug therapy/pathology/mortality, 80 and over, Cisplatin, Urinary Bladder Neoplasms/drug therapy/pathology, Urologic Neoplasms/drug therapy/pathology, Cabozantinib, Cisplatin-ineligible, Pembrolizumab, Platinum-ineligible, Urothelial carcinoma

Dateibeschreibung: application/pdf

Relation: European urology oncology; https://doi.org/10.1016/j.euo.2025.04.005; https://hdl.handle.net/1813/117951

Verfügbarkeit: https://hdl.handle.net/1813/117951

Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma

Autoren: Gutzmer, Ralf Leiter, Ulrike Mohr, Peter et al.

Quelle: BMC Cancer
Bmc Cancer
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Instituto de Investigación Sanitaria La Fe (IIS La Fe)
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)

Schlagwörter: Male, Adult, Aged, 80 and over, ddc:610, Skin Neoplasms, Pyridines, Research, Biphenyl Compounds, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Antineoplastic Agents, Middle Aged, Dysgeusia, Sonidegib, Hedgehog pathway inhibitors, Young Adult, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Carcinoma, Basal Cell, Basal cell carcinoma, Humans, Female, RC254-282, Antineoplastic Agents/adverse effects [MeSH], Aged, 80 and over [MeSH], Carcinoma, Basal Cell/drug therapy [MeSH], Aged [MeSH], Pyridines/adverse effects [MeSH], Antineoplastic Agents/administration, Skin Neoplasms/drug therapy [MeSH], Biphenyl Compounds/therapeutic use [MeSH], Male [MeSH], Dysgeusia/epidemiology [MeSH], Biphenyl Compounds/adverse effects [MeSH], Dysgeusia/chemically induced [MeSH], Female [MeSH], Pyridines/therapeutic use [MeSH], Adult [MeSH], Humans [MeSH], Pyridines/administration, Treatment Outcome [MeSH], Middle Aged [MeSH], Carcinoma, Basal Cell/pathology [MeSH], Skin Neoplasms/pathology [MeSH], Young Adult [MeSH], Antineoplastic Agents/therapeutic use [MeSH], Aged

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39538176
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=21993
https://doaj.org/article/f6af041d3b7c44cf9ec6506be11d5de8
https://hss-opus.ub.ruhr-uni-bochum.de/opus4/frontdoor/index/index/docId/11827
https://hss-opus.ub.ruhr-uni-bochum.de/opus4/files/11827/GutzmerRalf14112024.pdf
https://nbn-resolving.org/urn:nbn:de:hbz:294-118274
https://repository.publisso.de/resource/frl:6493652

Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)

Autoren: Guilherme Nader-Marta Christian Singer Dominik Hlauschek et al.

Quelle: Breast Cancer Res
Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024)

Schlagwörter: Endocrine therapy, Adult, Receptor, ErbB-2, Pyridines, Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Breast Neoplasms, Palbociclib, Middle Aged, Antibody–drug conjugates, Aged [MeSH], HER2-low, Receptor, ErbB-2/metabolism [MeSH], Breast cancer, Receptor, ErbB-2/genetics [MeSH], Neoplasm Staging [MeSH], Piperazines/therapeutic use [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Pyridines/therapeutic use [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Humans [MeSH], Breast Neoplasms/genetics [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Biomarkers, Tumor/metabolism [MeSH], Prognosis [MeSH], Prognosis, Piperazines, Receptors, Estrogen, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Female, RC254-282, Aged, Neoplasm Staging

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39375745
https://doaj.org/article/c4f4965043a847fba7a786c64cdbe554
https://repository.publisso.de/resource/frl:6500183

Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123)

Autoren: David Witte Ina Pretzell Timm M Reissig et al.

Weitere Verfasser: David Witte Ina Pretzell Timm M Reissig et al.

Quelle: J Cancer Res Clin Oncol

Schlagwörter: Research, Pancreatic cancer, MEK inhibitor, CDK inhibitor, Autophagy, Targeted therapy, Molecular guided treatment, Male, Adult, Aged, 80 and over, Pyridones, Pyridines, Aged, 80 and over [MeSH], Aged [MeSH], Pancreatic Neoplasms/pathology [MeSH], Hydroxychloroquine/therapeutic use [MeSH], Pyridones/administration, Pyridones/therapeutic use [MeSH], Piperazines/administration, Male [MeSH], Piperazines/therapeutic use [MeSH], Female [MeSH], Pyridines/therapeutic use [MeSH], Adult [MeSH], Humans [MeSH], Pyridines/administration, Retrospective Studies [MeSH], Middle Aged [MeSH], Pancreatic Neoplasms/drug therapy [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Pyrimidinones/administration, Hydroxychloroquine/administration, Pyrimidinones/therapeutic use [MeSH], Medizin, Pyrimidinones, Middle Aged, Piperazines, ddc, Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Retrospective Studies, Aged, Hydroxychloroquine

Dateibeschreibung: application/pdf; pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39352477
https://resolver.sub.uni-goettingen.de/purl?gro-2/146427
https://repository.publisso.de/resource/frl:6498139
https://mediatum.ub.tum.de/1770790
https://www.ncbi.nlm.nih.gov/pubmed/39352477
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85205447265
https://doi.org/10.1007/s00432-024-05954-5

REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.

Autoren: Mayer, Stephan A Bruder, Nicolas Citerio, Giuseppe et al.

Weitere Verfasser: Mayer, Stephan A Bruder, Nicolas Citerio, Giuseppe et al.

Quelle: Journal of Neurosurgery, 142 (1), 98 - 109 (2025-01-01)

Schlagwörter: aneurysm, cerebral ischemia, cerebral vasospasm, clazosentan, endothelin-1, subarachnoid hemorrhage, vascular disorders, Pyridines, Dioxanes, Pyrimidines, Sulfonamides, Tetrazoles, Humans, Male, Middle Aged, Female, Double-Blind Method, Aged, Prospective Studies, Treatment Outcome, Adult, Vasospasm, Intracranial/etiology, Vasospasm, Intracranial/prevention & control, Vasospasm, Intracranial/drug therapy, Vasospasm, Intracranial/diagnostic imaging, Subarachnoid Hemorrhage/complications, Subarachnoid Hemorrhage/diagnostic imaging, Pyridines/therapeutic use, Pyridines/adverse effects, Pyridines/administration & dosage, Dioxanes/therapeutic use, Dioxanes/adverse effects, Pyrimidines/therapeutic use, Pyrimidines/adverse effects, Pyrimidines/administration & dosage, Brain Ischemia/prevention & control, Brain Ischemia/etiology, Sulfonamides/therapeutic use, Sulfonamides/adverse effects, Sulfonamides/administration & dosage, Tetrazoles/therapeutic use, Tetrazoles/adverse effects, Brain Ischemia, Vasospasm, Intracranial, Surgery, Neurology (clinical), Human health sciences, Neurology, Anesthesia & intensive care, Sciences de la santé humaine, Neurologie, Anesthésie & soins intensifs

Relation: https://thejns.org/view/journals/j-neurosurg/aop/article-10.3171-2024.4.JNS232191/article-10.3171-2024.4.JNS232191.xml; urn:issn:0022-3085; urn:issn:1933-0693

Zugangs-URL: https://orbi.uliege.be/handle/2268/328394

Situational prevention in migraine: are we doing the right thing?: are we doing the right thing?

Autoren: Lanfranco Pellesi Paolo Martelletti

Quelle: J Headache Pain
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-3 (2024)

Schlagwörter: Medication overuse, Rimegepant, Headache Disorders, Pyridines, Migraine Disorders, Comment, Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Migraine Disorders/prevention & control, Piperidines, Calcitonin Gene-Related Peptide Receptor Antagonists, Headache Disorders, Secondary, Secondary/prevention & control, Medicine, Humans, CGRP, Pyridines/therapeutic use, Migraine

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39174943
https://doaj.org/article/d955bca907cf4bb0b905672e96ab9dff

Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis

Autoren: Rosemary E Maher Urszula M Cytlak-Chaudhuri Saad Aleem et al.

Quelle: Maher, R E, Cytlak-Chaudhuri, U M, Aleem, S, Barry, P, Brice, D P, Caamaño Gutiérrez, E, Driver, K, Emmott, E, Rothwell, A, Smith, E, Travis, M, Lee, D, McNamara, P S, Waller, I, Smith, J A, Jones, A & Lord, R W 2025, 'Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis', Thorax, vol. 80, no. 9, pp. 604-615. https://doi.org/10.1136/thorax-2024-222242

Schlagwörter: Male, Adult, Quinolones/therapeutic use, Adolescent, Aminophenols/therapeutic use, Drug Combinations, Young Adult, Pyrrolidines/therapeutic use, Pyrazoles/therapeutic use, Inflammation/drug therapy, Chloride Channel Agonists/therapeutic use, Quinolines, Humans, Female, Cystic Fibrosis/drug therapy, Longitudinal Studies, Benzodioxoles/therapeutic use, Child, Indoles/therapeutic use, Pyridines/therapeutic use

Zugangs-URL: https://research.manchester.ac.uk/en/publications/b960bb17-a719-4d1e-abdc-b448a1922b6a
https://doi.org/10.1136/thorax-2024-222242

Vorasidenib bei niedriggradigen Gliomen – neues Therapieprinzip mit offenen Fragen zu den Langzeitergebnissen

Autoren: Seidel, Clemens Nicolay, Nils H.

Quelle: Strahlenther Onkol

Schlagwörter: Glioma/drug therapy [MeSH], Brain Neoplasms/radiotherapy [MeSH], Pyridines/therapeutic use [MeSH], Diamines/therapeutic use [MeSH], Humans [MeSH], Pyridines/adverse effects [MeSH], Literatur Kommentiert, Brain Neoplasms/drug therapy [MeSH], Diamines/adverse effects [MeSH]

Zugangs-URL: https://repository.publisso.de/resource/frl:6516110

Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy

Autoren: Zuckermann, Marc He, Chen Andrews, Jared et al.

Quelle: Mol Cancer
Molecular Cancer, Vol 23, Iss 1, Pp 1-19 (2024)

Schlagwörter: 0301 basic medicine, Oncogene Proteins, Fusion, Pyridines, MET inhibition, Mice, 03 medical and health sciences, 0302 clinical medicine, Crizotinib, Cell Line, Tumor, Animals, Humans, Anilides, Combination therapy, Child, Protein Kinase Inhibitors, RC254-282, Radiosensitization, Preclinical trials, Brain Neoplasms, Triazines, Research, Imidazoles, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Pediatric-type diffuse high-grade glioma, Glioma, Proto-Oncogene Proteins c-met, Xenograft Model Antitumor Assays, 3. Good health, Disease Models, Animal, Cell Line, Tumor [MeSH], Neoplasm Grading [MeSH], Imidazoles [MeSH], Proto-Oncogene Proteins c-met/genetics [MeSH], Crizotinib/pharmacology [MeSH], Glioma/drug therapy [MeSH], Glioma/pathology [MeSH], Xenograft Model Antitumor Assays [MeSH], Benzamides/therapeutic use [MeSH], Child [MeSH], Disease Models, Animal [MeSH], Glioma/therapy [MeSH], Crizotinib/therapeutic use [MeSH], Benzamides/pharmacology [MeSH], Female [MeSH], Pyridines/pharmacology [MeSH], Brain Neoplasms/radiotherapy [MeSH], Brain Neoplasms/genetics [MeSH], Protein Kinase Inhibitors/pharmacology [MeSH], Pyridines/therapeutic use [MeSH], Humans [MeSH], Oncogene Proteins, Fusion/genetics [MeSH], Animals [MeSH], Protein Kinase Inhibitors/therapeutic use [MeSH], Capmatinib, Proto-Oncogene Proteins c-met/metabolism [MeSH], Mice [MeSH], Proto-Oncogene Proteins c-met/antagonists, Glioma/genetics [MeSH], Triazines [MeSH], Anilides/pharmacology [MeSH], Brain Neoplasms/drug therapy [MeSH], Oncogene Proteins, Fusion/metabolism [MeSH], Brain Neoplasms/pathology [MeSH], Benzamides, Female, Neoplasm Grading

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38849845
https://doaj.org/article/c4e30eaef7d54080a0db2c1628bcebbf
https://repository.publisso.de/resource/frl:6493228

Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study: insights from the ETNA-AF-Europe study

Autoren: Georges H. Mairesse Frank Cools ETNA-AF-Europe principal investigators from Belgium et al.

Weitere Verfasser: Georges H. Mairesse Frank Cools ETNA-AF-Europe principal investigators from Belgium et al.

Quelle: Neth Heart J
Acta Cardiologica, 76, 4, pp. 431-439
Netherlands Heart Journal, 29, 3, pp. 158-167
Netherlands heart journal
Acta cardiologica

Schlagwörter: Cardiac & Cardiovascular Systems, Cardiologie et circulation, Pyridines, Clinical trial, phase IV, Belgium, Atrial Fibrillation, off-label use, Prospective Studies, Human health sciences, 1102 Cardiorespiratory Medicine and Haematology, Pyridines/therapeutic use, Cardiology - Radboud University Medical Center, Netherlands, Europe -- epidemiology, Netherlands -- epidemiology, clinical trial, stroke, 3. Good health, Stroke, Clinical trial, Europe, Factor Xa Inhibitors -- therapeutic use, Treatment Outcome, Original Article, haemorrhage, 3201 Cardiovascular medicine and haematology, Life Sciences & Biomedicine, ROUTINE CLINICAL-PRACTICE, management, phase iv, phase IV, trends, anticoagulants, k oral anticoagulants, Atrial Fibrillation -- complications -- drug therapy -- epidemiology, NDU3J18APO (edoxaban), Thiazoles -- therapeutic use, Netherlands/epidemiology, Systèmes cardiovasculaire & respiratoire, Sciences de la santé humaine, WARFARIN, Europe/epidemiology, Radboudumc 16: Vascular damage RIHS: Radboud Institute for Health Sciences, Thromboembolism, Cardiovascular & respiratory systems, Pyridines -- therapeutic use, MANAGEMENT, Belgium -- epidemiology, Off-label use, Humans, ETNA-AF-Europe principal investigators from Belgium and the Netherlands, K ORAL ANTICOAGULANTS, Factor Xa Inhibitors/therapeutic use, Belgium/epidemiology, Atrial Fibrillation/complications/drug therapy/epidemiology, Aged, Science & Technology, Anticoagulants, Off-Label Use, thromboembolism, TRENDS, warfarin, clinical trial, phase IV, Thiazoles, Cardiovascular System & Hematology, Haemorrhage, Thiazoles/therapeutic use, Cardiovascular System & Cardiology, Human medicine, routine clinical-practice, Factor Xa Inhibitors

Dateibeschreibung: 1 full-text file(s): application/pdf

Zugangs-URL: https://www.tandfonline.com/doi/pdf/10.1080/00015385.2020.1746095?needAccess=true
https://link.springer.com/content/pdf/10.1007/s12471-020-01518-7.pdf
https://pubmed.ncbi.nlm.nih.gov/33406996
https://pubmed.ncbi.nlm.nih.gov/33411231
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/233790
https://cris.maastrichtuniversity.nl/en/publications/580eb4d8-fbd9-40bd-bd5b-2993b5572a4c
https://doi.org/10.1007/s12471-020-01518-7
https://cris.maastrichtuniversity.nl/en/publications/e0358109-6f13-4ecd-99b9-0e2521732ffb
https://doi.org/10.1080/00015385.2020.1746095
https://cris.maastrichtuniversity.nl/en/publications/characteristics-of-patients-with-atrial-fibrillation-prescribed-e-2
https://link.springer.com/content/pdf/10.1007/s12471-020-01518-7.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904979
https://europepmc.org/article/PMC/PMC7904979
https://www.narcis.nl/publication/RecordID/oai%3Arepository.ubn.ru.nl%3A2066%2F233790
https://difusion.ulb.ac.be/vufind/Record/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/319156/Details
https://www.ncbi.nlm.nih.gov/pubmed/33406996
https://researchportal.vub.be/en/publications/characteristics-of-patients-with-atrial-fibrillation-prescribed-e
https://pubmed.ncbi.nlm.nih.gov/33406996/
https://www.narcis.nl/publication/RecordID/oai%3Acris.maastrichtuniversity.nl%3Apublications%2Fe0358109-6f13-4ecd-99b9-0e2521732ffb
https://cris.maastrichtuniversity.nl/en/publications/characteristics-of-patients-with-atrial-fibrillation-prescribed-e
https://www.tandfonline.com/doi/full/10.1080/00015385.2020.1746095
https://pure.amsterdamumc.nl/en/publications/e83d6afb-812e-44b3-96ab-a1dc55896423
https://doi.org/10.1007/s12471-020-01518-7
https://lirias.kuleuven.be/handle/123456789/669035
https://doi.org/10.1080/00015385.2020.1746095
https://repository.ubn.ru.nl//bitstream/handle/2066/238754/238754.pdf
https://repository.ubn.ru.nl/handle/2066/238754
https://repository.ubn.ru.nl//bitstream/handle/2066/233790/233790.pdf
https://hdl.handle.net/2066/233790
https://repository.uantwerpen.be/docstore/d:irua:4372
https://hdl.handle.net/10067/1749810151162165141
https://hdl.handle.net/10067/1750190151162165141
https://repository.uantwerpen.be/docstore/d:irua:4423
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/319130
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/319156
https://hdl.handle.net/11568/1140778
https://doi.org/10.1007/s12471-020-01518-7
https://biblio.vub.ac.be/vubir/(ff57e9aa-ae4a-4dea-9dfa-816b2868a195).html

Addressing treatment switching bias in the ALTA-1L trial with g-methods: exploring the impact of model specification

Autoren: Al Tawil, Amani McGrath, Sean Ristl, Robin et al.

Quelle: BMC Med Res Methodol
BMC Medical Research Methodology, Vol 24, Iss 1, Pp 1-22 (2024)

Schlagwörter: Medicine (General), Lung Neoplasms, Pyridines, 01 natural sciences, IPCW, 03 medical and health sciences, R5-920, Organophosphorus Compounds, 0302 clinical medicine, Crizotinib, Parametric g-formula, Humans, Treatment switching, 0101 mathematics, Proportional Hazards Models, Randomized Controlled Trials as Topic, Models, Statistical, Treatment-confounder feedback, Research, Survival analysis, Intention to Treat Analysis, 3. Good health, Time-dependent confounding, Pyrimidines, Treatment Outcome, Clinical Trials, Phase III as Topic, Pyrazoles, Crizotinib/therapeutic use [MeSH], Intention to Treat Analysis/methods [MeSH], Clinical Trials, Phase III as Topic/methods [MeSH], Pyridines/therapeutic use [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Pyrazoles/therapeutic use [MeSH], Randomized Controlled Trials as Topic/methods [MeSH], Proportional Hazards Models [MeSH], Pyrimidines/therapeutic use [MeSH], Clinical Trials, Phase III as Topic/statistics, Models, Statistical [MeSH], Randomized Controlled Trials as Topic/statistics, Lung Neoplasms/drug therapy [MeSH], Organophosphorus Compounds/therapeutic use [MeSH]

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39707229
https://doaj.org/article/39a5b1d6baf3408c83fa74836fe13a8f
https://repository.publisso.de/resource/frl:6491842
https://epub.ub.uni-muenchen.de/124722/

Case Series: Hyperbilirubinemia under elexacaftor/tezacaftor/ivacaftor in the presence of Gilbert’s syndrome

Autoren: Weitzel, Julia Welsner, Matthias Taube, Christian et al.

Quelle: BMC Pulm Med
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-5 (2024)

Schlagwörter: Adult, Male, 0301 basic medicine, Indoles, Pyrrolidines, Adolescent, Cystic Fibrosis, Pyridines, Medizin, Liver dysfunction, Case Report, Gilbert's syndrome, Quinolones, Aminophenols, Cystic fibrosis, Diseases of the respiratory system, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Humans, Elexacaftor/tezacaftor/ivacaftor, Pyrroles, Benzodioxoles, Glucuronosyltransferase, Hyperbilirubinemia, RC705-779, Cystic Fibrosis/drug therapy [MeSH], Hyperbilirubinemia/chemically induced [MeSH], Pyrazoles/adverse effects [MeSH], Benzodioxoles/adverse effects [MeSH], Drug Combinations [MeSH], Pyridines/adverse effects [MeSH], Drug intolerance, Pyrazoles/therapeutic use [MeSH], Pyrroles/adverse effects [MeSH], Benzodioxoles/therapeutic use [MeSH], Aminophenols/therapeutic use [MeSH], Male [MeSH], Indoles/adverse effects [MeSH], Adolescent [MeSH], Female [MeSH], Quinolones/adverse effects [MeSH], Pyridines/therapeutic use [MeSH], Adult [MeSH], Cystic Fibrosis/complications [MeSH], Humans [MeSH], Gilbert Disease/drug therapy [MeSH], Pyrrolidines [MeSH], Quinolines [MeSH], Young Adult [MeSH], Glucuronosyltransferase/genetics [MeSH], Gilbert Disease/genetics [MeSH], Aminophenols/adverse effects [MeSH], Quinolones/therapeutic use [MeSH], 3. Good health, Drug Combinations, Quinolines, Pyrazoles, Female, Gilbert Disease

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38956524
https://doaj.org/article/e7f10fbf6acf4c76954ab790ee4ad480
https://repository.publisso.de/resource/frl:6524398
https://www.ncbi.nlm.nih.gov/pubmed/38956524
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85197650229
https://doi.org/10.1186/s12890-024-03114-6

Direkte orale antikoagulantia til behandling af cancerassocieret trombose

Autoren: Poulsen, Maja Hellfritzsch Kümler, Thomas Lamberts, Morten Kjøbek et al.

Quelle: Poulsen, M H, Kümler, T, Lamberts, M K, Ruhlmann, C H & Grove, E L 2024, ' Direkte orale antikoagulantia til behandling af cancerassocieret trombose ', Ugeskrift for Laeger, bind 186, nr. 42 . https://doi.org/10.61409/V04240299

Schlagwörter: Oral, Anticoagulants/administration & dosage, Pyrazoles/therapeutic use, Administration, Thiazoles/therapeutic use, Humans, Thrombosis/drug therapy, Neoplasms/complications, Pyridones/therapeutic use, Factor Xa Inhibitors/therapeutic use, Pyridines/therapeutic use, Rivaroxaban/therapeutic use

Dateibeschreibung: application/pdf

Zugangs-URL: https://curis.ku.dk/ws/files/446778478/V04240299_WEB.pdf
https://portal.findresearcher.sdu.dk/da/publications/21eb6a97-1901-46d6-b23d-ecdc8b19d78d
https://doi.org/10.61409/V04240299